ML

Manik Lal Saha

Director Director DIN 02673487
DIN 02673487 First appointment Sep 2003 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Sep 2003
Shareholding value •••• Premium profile

About Manik Lal Saha

Data last updated:

Manik Lal Saha was a Director at Franco-Indian Pharmaceuticals Private Limited (2009–2014) and Director at Wardex Pharmaceuticals Private Limited (2003–2014). The companies operate in Pharma.

DIN 02673487
Primary Designation Director
Industry Pharma
First Appointment 27 Sep 2003

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director29 Jan 20091959₹989 Cr (FY 2024)Active
Director27 Sep 20031946₹158 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Franco-Indian Pharmaceuticals Private Limited
Wardex Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Manik Lal Saha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manik Lal Saha

Manik Lal Saha was first appointed on 27 Sep 2003 as Director at Wardex Pharmaceuticals Private Limited. The most recent appointment on record is 29 Jan 2009 at Franco-Indian Pharmaceuticals Private Limited.

Manik Lal Saha held 2 earlier board appointments: Franco-Indian Pharmaceuticals Private Limited (Director, 29 Jan 2009 to 30 Apr 2014); Wardex Pharmaceuticals Private Limited (Director, 27 Sep 2003 to 30 Apr 2014).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available